Loading…
Lobbying Spend
—
Filings
17
Firms Hired
1
Active Period
2007–2010
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
American Middle Class Tax (AMT) Relief Act of 2007
2010 · first_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 3200, Americas Affordable Health Choices Act; Issues related to the Eshoo amendment, 001, issues related to biosimilars, and Sec. 1232, the End-Stage Renal Disease (ESRD) bundling formula H.R. 3590, The Patient Protection and Affordable Care Act; Issues related to subtitle A, "biologics price competition and innovation H.R. 4872, The Reconciliation Act of 2010
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3590
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 3200, Americas Affordable Health Choices Act; Issues related to the Eshoo amendment, 001, issues related to biosimilars, and Sec. 1232, the End-Stage Renal Disease (ESRD) bundling formula H.R. 3590, The Patient Protection and Affordable Care Act; Issues related to subtitle A, "biologics price competition and innovation H.R. 4872, The Reconciliation Act of 2010
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1548
America's Affordable Health Choices Act of 2009
2010 · first_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 3200, Americas Affordable Health Choices Act; Issues related to the Eshoo amendment, 001, issues related to biosimilars, and Sec. 1232, the End-Stage Renal Disease (ESRD) bundling formula H.R. 3590, The Patient Protection and Affordable Care Act; Issues related to subtitle A, "biologics price competition and innovation H.R. 4872, The Reconciliation Act of 2010
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3200
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 3200, Americas Affordable Health Choices Act; Issues related to the Eshoo amendment, 001, issues related to biosimilars, and Sec. 1232, the End-Stage Renal Disease (ESRD) bundling formula
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1548
America's Affordable Health Choices Act of 2009
2009 · fourth_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 3200, Americas Affordable Health Choices Act; Issues related to the Eshoo amendment, 001, issues related to biosimilars, and Sec. 1232, the End-Stage Renal Disease (ESRD) bundling formula
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3200
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 3200, Americas Affordable Health Choices Act; Issues related to the Eshoo amendment, 001, issues related to biosimilars, and Sec. 1232, the End-Stage Renal Disease (ESRD) bundling formula
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1548
America's Affordable Health Choices Act of 2009
2009 · third_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1548, Pathway for Biosimilars Act of 2009 H.R. 3200, Americas Affordable Health Choices Act; Issues related to the Eshoo amendment, 001, issues related to biosimilars, and Sec. 1232, the End-Stage Renal Disease (ESRD) bundling formula
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3200
America's Affordable Health Choices Act of 2009
2009 · third_quarter · Firm: CAPITOL SOLUTIONS
H.R. 5629, To establish a pathway for licensure of biosimilars biological products H.R. 3200, Americas Affordable Health Choices Act; Issues related to the Eshoo amendment, 001, follow-on biologics, and Sec. 1232, the End-Stage Renal Disease (ESRD) bundling formula
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3200
Oil Spill Accountability and Environmental Protection Act of 2010
2009 · third_quarter · Firm: CAPITOL SOLUTIONS
H.R. 5629, To establish a pathway for licensure of biosimilars biological products H.R. 3200, Americas Affordable Health Choices Act; Issues related to the Eshoo amendment, 001, follow-on biologics, and Sec. 1232, the End-Stage Renal Disease (ESRD) bundling formula
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5629
Oil Spill Accountability and Environmental Protection Act of 2010
2009 · second_quarter · Firm: CAPITOL SOLUTIONS
Issues related to State Children's Health Insurance Program (SCHIP) H.R. 5629, To establish a pathway for licensure of biosimilars biological products Issues related to ESRD bundling formula
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5629
Oil Spill Accountability and Environmental Protection Act of 2010
2009 · first_quarter · Firm: CAPITOL SOLUTIONS
Issues related to State Children's Health Insurance Program (SCHIP) H.R. 1, The American Recovery and Reinvestment Act of 2009; Issues related to medicare proportionality H.R. 5629, To establish a pathway for licensure of biosimilars biological products
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5629
Access to Life-Saving Medicine Act
2008 · fourth_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1956, To amend the Public Health Services Act to provide for the approval of similar biological products H.R. 1038, To provide for the licensing of comparable and interchangable biological products H.R. 5629, To establish a pathway for licensure of biosimilars biological products
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1038
Patient Protection and Innovative Biologic Medicines Act of 2007
2008 · fourth_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1956, To amend the Public Health Services Act to provide for the approval of similar biological products H.R. 1038, To provide for the licensing of comparable and interchangable biological products H.R. 5629, To establish a pathway for licensure of biosimilars biological products
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1956
H.R. 1956, To amend the Public Health Services Act to provide for the approval of similar biological products H.R. 1038, To provide for the licensing of comparable and interchangable biological products H.R. 5629, To establish a pathway for licensure of biosimilars biological products
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5629
Access to Life-Saving Medicine Act
2008 · third_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1956, To amend the Public Health Services Act to provide for the approval of similar biological products H.R. 1038, To provide for the licensing of comparable and interchangable biological products H.R. 5629, To establish a pathway for licensure of biosimilars biological products
Client expense: — · Firm income: $100,000
Matched citations: H.R. 1038
Patient Protection and Innovative Biologic Medicines Act of 2007
2008 · third_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1956, To amend the Public Health Services Act to provide for the approval of similar biological products H.R. 1038, To provide for the licensing of comparable and interchangable biological products H.R. 5629, To establish a pathway for licensure of biosimilars biological products
Client expense: — · Firm income: $100,000
Matched citations: H.R. 1956
H.R. 1956, To amend the Public Health Services Act to provide for the approval of similar biological products H.R. 1038, To provide for the licensing of comparable and interchangable biological products H.R. 5629, To establish a pathway for licensure of biosimilars biological products
Client expense: — · Firm income: $100,000
Matched citations: H.R. 5629
Access to Life-Saving Medicine Act
2008 · second_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1956, To amend the Public Health Service Act to provide for the approval of similar biological products H.R. 1038, To provide for the licensing of comparable and interchangeable biological products H.R. 5629, To establish a pathway for licensure of biosimilar biological products
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1038
Patient Protection and Innovative Biologic Medicines Act of 2007
2008 · second_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1956, To amend the Public Health Service Act to provide for the approval of similar biological products H.R. 1038, To provide for the licensing of comparable and interchangeable biological products H.R. 5629, To establish a pathway for licensure of biosimilar biological products
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1956
H.R. 1956, To amend the Public Health Service Act to provide for the approval of similar biological products H.R. 1038, To provide for the licensing of comparable and interchangeable biological products H.R. 5629, To establish a pathway for licensure of biosimilar biological products
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5629
Access to Life-Saving Medicine Act
2008 · first_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1956, Patient Protection and Innovative Biologics Medicines Act of 2007 H.R. 1038, Access to Life-saving Medicines Act H.R. 5629, Pathway for Biosimilars Act
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1038
Patient Protection and Innovative Biologic Medicines Act of 2007
2008 · first_quarter · Firm: CAPITOL SOLUTIONS
H.R. 1956, Patient Protection and Innovative Biologics Medicines Act of 2007 H.R. 1038, Access to Life-saving Medicines Act H.R. 5629, Pathway for Biosimilars Act
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1956
H.R. 1956, Patient Protection and Innovative Biologics Medicines Act of 2007 H.R. 1038, Access to Life-saving Medicines Act H.R. 5629, Pathway for Biosimilars Act
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5629
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services within the Department of Health and Human Services relating to Medicare coverage for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions.
2007 · year_end · Firm: CAPITOL SOLUTIONS
Medicare reimbursement and coverage issues H.J. Res 54 Resolution of Disapproval regarding Medicare's coverage of ESAs
Client expense: — · Firm income: $160,000
Matched citations: H.J. Res 54
H.R. 1956 To amend the Public Health Service Act to provide for the approval of similar biological products H.R. 1038 provide for the licensing of comparable and interchangeable biological products
Client expense: — · Firm income: $160,000
Matched citations: H.R. 1038
Source: Senate LDA